104 related articles for article (PubMed ID: 17203035)
1. When the party's over.
Wadman M
Nature; 2007 Jan; 445(7123):13. PubMed ID: 17203035
[No Abstract] [Full Text] [Related]
2. Blockbuster drug bows out.
Ledford H
Nature; 2011 Nov; 480(7375):16-7. PubMed ID: 22129701
[No Abstract] [Full Text] [Related]
3. Drug designed to raise HDL levels falls down.
Honey K
J Clin Invest; 2007 Feb; 117(2):282. PubMed ID: 17273546
[No Abstract] [Full Text] [Related]
4. The failure of torcetrapib: was it the molecule or the mechanism?
Tall AR; Yvan-Charvet L; Wang N
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
[No Abstract] [Full Text] [Related]
5. The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
Doggrell SA
Expert Opin Pharmacother; 2008 Apr; 9(6):875-8. PubMed ID: 18377331
[TBL] [Abstract][Full Text] [Related]
6. The $10 billion pill.
Simons J
Fortune; 2003 Jan; 147(1):58-62, 66, 68. PubMed ID: 12602122
[No Abstract] [Full Text] [Related]
7. Realism in drug discovery-could Cassandra be right?
Horrobin DF
Nat Biotechnol; 2001 Dec; 19(12):1099-100. PubMed ID: 11731767
[No Abstract] [Full Text] [Related]
8. Industry shifts focus to immunology and cancer.
Ledford H
Nature; 2008 Nov; 456(7218):6. PubMed ID: 19004069
[No Abstract] [Full Text] [Related]
9. Three planks of the Pirate Party's platform that matter to doctors.
Ingdahl W
BMJ; 2011 Dec; 343():d8101. PubMed ID: 22187193
[No Abstract] [Full Text] [Related]
10. Monstrous crowing.
Nat Biotechnol; 2001 Aug; 19(8):693. PubMed ID: 11479541
[No Abstract] [Full Text] [Related]
11. Overcoming the challenges in the pharma/biotech industry.
Graul AI; Prous JR
Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
[TBL] [Abstract][Full Text] [Related]
12. A stronger role for science.
Nat Rev Drug Discov; 2011 Mar; 10(3):159. PubMed ID: 21469392
[TBL] [Abstract][Full Text] [Related]
13. Drug giants turn their backs on RNA interference.
Ledford H
Nature; 2010 Nov; 468(7323):487. PubMed ID: 21107398
[No Abstract] [Full Text] [Related]
14. Niche drugs aren't a cheap alternative to blockbusters.
Tracey WR
Nature; 2007 Feb; 445(7130):818. PubMed ID: 17314952
[No Abstract] [Full Text] [Related]
15. Reinventing an industry.
Mandavilli A
Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
[No Abstract] [Full Text] [Related]
16. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
Brun J; Ohlsson-Onerud A; Sörensen N
Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
[No Abstract] [Full Text] [Related]
17. To make better therapeutics, companies strive to increase the content of results and get them faster.
Szpir M
Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
[No Abstract] [Full Text] [Related]
18. Pharma consolidates its grip on post-antibody landscape.
Sheridan C
Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
[No Abstract] [Full Text] [Related]
19. Fake drugs: a problem for all.
McHugh A
Br J Hosp Med (Lond); 2006 Oct; 67(10):551. PubMed ID: 17073011
[No Abstract] [Full Text] [Related]
20. A place in the sun.
Abbott A
Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
[No Abstract] [Full Text] [Related]
[Next] [New Search]
